Loading market dashboard
Poolbeg Pharma PLC
POLBFHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a...
Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) for lead asset POLB 001. Cavendish reiterated its 'buy' rating and 19p target price, noting the FDA discussions de-risk the overall development programme by ensuring that the regulator agrees, at least in principle, that the data produced through the clinical programme could support approval.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a pre-investigational new drug (IND) meeting for its lead asset POLB 001. POLB 001 is being developed as a potential preventative therapy for cytokine release syndrome (CRS), a serious side effect triggered by cancer immunotherapy treatments.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received a Canadian patent approval covering the use of its POLB 001 drug candidate in preventing cancer immunotherapy-induced cytokine release syndrome (CRS), a potentially life-threatening immune overreaction triggered by certain cancer treatments. The grant is the second national approval within Poolbeg's CRS patent family, following a ruling by IP Australia in March 2026.
Poolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call Transcript
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is heading into its most consequential period since flotation, as interim data from its lead drug candidate POLB 001 approaches and a second trial prepares to start. POLB 001 is designed as an oral preventative therapy for cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction that affects more than 70% of patients receiving CAR T-cell and bispecific antibody cancer treatments.
9.18am: FTSE battles higher The FTSE 100 has fought its way into the green, up 20 points at 10,341. BP and Shell are doing a lot of the heavy lifting, up...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is advancing partnering discussions with multiple pharmaceutical companies as it moves towards a series of near-term clinical data readouts that management believes could catalyse a deal. Its lead programme, POLB 001, is being developed as a preventative therapy for Cytokine Release Syndrome (CRS), a potentially life-threatening immune overreaction triggered by certain cancer immunotherapies, particularly bispecific antibodies, which work by simultaneously binding to cancer cells and immune cells to direct an attack on tumours.
8.15am: FTSE drops as miners, builders and airlines fall The FTSE 100 has dropped 44 points to 10,623 in opening trades, with miners, airlines,...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO, Jeremy Skillington, talked with Proactive about recent progress alongside Principal Scientist Liam...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO, Jeremy Skillington, talked with Proactive about recent progress alongside Principal Scientist Liam Tremble, highlighting key regulatory and commercial developments for POLB 001. Tremble explained that the company has secured full regulatory approval from the MHRA, alongside HRA and ARSAC clearances, marking a major milestone that allows the POLB 001 clinical trial to proceed in the UK.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) shares rose as much as 8% on Wednesday after receipt of Clinical Trial Authorisation from the UK...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) shares rose as much as 8% on Wednesday after receipt of Clinical Trial Authorisation from the UK medicines regulator for its POLB 001 TOPICAL study. Cavendish said the milestone represents a key de-risking event and clears the final hurdle ahead of patient screening.
9.51am: ONS pushes back jobs data reform delivery date The Office for National Statistics said the quality of UK economic data is improving, but key reforms...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has received clinical trial authorisation from...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has received clinical trial authorisation from the UK Medicines and Healthcare products Regulatory Agency for its TOPICAL trial, with interim data expected this summer. The trial is investigating POLB 001, which is being developed as a potential first-approved preventative therapy for cytokine release syndrome (CRS), a serious immune reaction triggered by cancer immunotherapies, including CAR T-cell therapies and bispecific antibodies.
Twilio Inc (NYSE:TWLO) has been upgraded by Jefferies analysts who see increased confidence in the company’s positioning within the emerging Voice AI...
Accesso Technology Group PLC (LSE:ACSO, OTC:LOQPF, FRA:LQG) CEO Steve Brown says the acquisition of Dexibit is a step change in how the company delivers...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) earlier this week announced that it had secured its first national patent grant covering its POLB-001...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) earlier this week announced that it had secured its first national patent grant covering its POLB-001 programme in cancer immunotherapy-induced cytokine release syndrome (CRS), marking a significant step in the company's expansion into oncology. Chief executive Jeremy Skillington said the patent, granted by IP Australia, covered the use of P38 MAPK inhibitors, including POLB-001, for preventing CRS linked to cancer immunotherapy.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF)shares rose as much as 10% in Tuesday morning trading after the AIM-listed biopharmaceutical company...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF)shares rose as much as 10% in Tuesday morning trading after the AIM-listed biopharmaceutical company secured its first national patent grant for POLB 001. This is the drug developer's lead candidate for preventing a serious side effect of cancer immunotherapy.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has reached a significant milestone in its intellectual property strategy after Australia granted the first national patent in its programme targeting a serious side effect of cancer immunotherapy. IP Australia, the Australian patent office, has granted protection covering the use of any p38 MAPK inhibitor.
Oracle Corp (NYSE:ORCL, XETRA:ORC)’s latest outlook as an early sign that enterprise software vendors are beginning to demonstrate tangible returns from...
Bumble Inc (NASDAQ:BMBL) shares rose more than 36% to just shy of $4 in post-earnings trading after the dating-app company reported quarterly revenue...
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is currently chief medical officer at Cellectis, the French biotechnology company focused on allogeneic CAR-T therapies, which engineer a patient's immune cells to target and destroy cancer.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its...
